RxDoctor Payments Data

Ashim Dayalan, MD

Internal Medicine · Pittsburgh, PANPI 1376508028

Payments from drug & device makers

$25,684in general payments, 2019–2025

Across 1,531 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$25,588100%
  • Education$490%
  • Gifts$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)236$3,943
Novo Nordisk265$3,473
AstraZeneca109$2,162
Johnson & Johnson87$1,809
GSK97$1,491
Boehringer Ingelheim77$1,466
Amgen80$1,444
Pfizer100$1,135
Daiichi Sankyo Inc.31$710
Lilly USA, LLC42$696
Abbott38$582
Novartis43$514
Amarin Pharma, Inc.26$426
Orexo US, Inc.23$397
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)15$321
Takeda Pharmaceuticals U.S.A., Inc.21$292
Merck22$277
Medtronic(2 entities)9$267
E.r. Squibb & Sons, L.L.C.16$265
Bayer14$253
Amneal Pharmaceuticals LLC12$246
Cequr Corporation4$235
Astellas Pharma US Inc10$226
Shield Therapeutics Inc15$221
Phathom Pharmaceuticals, Inc.7$204
Exact Sciences6$162
Biohaven Pharmaceutical Holding Company Ltd.10$148
Idorsia Pharmaceuticals US Inc7$145
Kowa Pharmaceuticals America, Inc.8$140
Ironwood Pharmaceuticals, Inc8$134
Radius Health, Inc.9$131
Axsome Therapeutics, Inc.2$127
Lundbeck LLC6$124
Dexcom, Inc.7$121
Scilex Pharmaceuticals Inc.1$104
Sanofi-aventis U.S. LLC7$103
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$101
Teva Pharmaceuticals USA, Inc.5$95
Currax Pharmaceuticals LLC3$90
Xeris Pharmaceuticals, Inc.4$89
Esperion Therapeutics, Inc.4$84
Biohaven Pharmaceuticals, Inc.4$75
Eisai Inc.4$72
Braeburn Inc.4$69
IBSA Pharma Inc.4$65
Almatica Pharma LLC3$51
Tosoh Bioscience, Inc.1$47
Actelion Pharmaceuticals US, Inc.2$44
Indivior Inc.3$42
Boston Scientific2$38
Corcept Therapeutics2$34
Otsuka America Pharmaceutical, Inc.2$32
Inspire Medical Systems, Inc.1$26
BETA Bionics, Inc.1$23
Alvogen Inc1$23
Nevro Corp.1$22
Acadia Pharmaceuticals Inc1$21
Ultragenyx Pharmaceutical Inc.1$16
Tactile Systems Technology Inc1$16
Biodelivery Sciences International, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,684 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$215,545
Medicare patients
364
Services billed
5,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$197,237
XareltoRivaroxaban135$107,874
OzempicSemaglutide79$99,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$72,404
FarxigaDapagliflozin Propanediol38$43,572
JardianceEmpagliflozin36$37,832
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl199$28,372
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$24,835
ProliaDenosumab14$24,574
Synjardy XrEmpagliflozin/Metformin Hcl29$19,130
Breo ElliptaFluticasone/Vilanterol33$17,593
Xigduo XrDapaglifloz Propaned/Metformin16$17,381
MounjaroTirzepatide16$16,535
Atorvastatin Calcium911$9,353
Mesalamine12$7,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,135$197,237204 claims
Johnson & JohnsonXarelto$1,809$107,874135 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$1,491$101,228136 claims
Novo NordiskOzempic$3,473$99,60679 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,466$56,96165 claims
AstraZenecaFarxiga$2,162$43,57238 claims
AmgenProlia$1,444$24,57414 claims
Lilly USA, LLCMounjaro$696$16,53516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$246$8,353485 claims
MerckJanumet$277$7,01913 claims
AbbVieSynthroid$3,943$3,58263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →